Valuation: Viking Therapeutics, Inc.

Market Cap 4.51B 3.95B 3.64B 3.36B 6.38B 430B 6.49B 43.49B 17.08B 212B 16.94B 16.57B 729B P/E 2026 *
-8.08x
P/E 2027 * -8.4x
Enterprise Value 4.06B 3.55B 3.28B 3.03B 5.74B 387B 5.84B 39.15B 15.38B 191B 15.25B 14.92B 656B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.21%
Yield 2026 *
-
Yield 2027 * -
1 day-5.54%
1 week+3.79%
Current month-0.38%
1 month+35.83%
3 months+13.43%
6 months+21.48%
Current year+10.46%
1 week 37.1
Extreme 37.1
42.79
1 month 29
Extreme 29
42.79
Current year 25.77
Extreme 25.77
42.79
1 year 22.96
Extreme 22.959
43.15
3 years 8.28
Extreme 8.28
99.41
5 years 2.02
Extreme 2.02
99.41
10 years 0.88
Extreme 0.88
99.41
Manager TitleAgeSince
Chief Executive Officer 60 2012-09-23
Director of Finance/CFO 55 2021-01-03
Chief Tech/Sci/R&D Officer 57 2026-06-10
Director TitleAgeSince
Chairman 68 2015-04-30
Chairman 60 2012-09-23
Director/Board Member 53 2014-04-30
Date Insider Type Main position Quantity % Market Cap.
05-31Free

Chief Technology Officer

190,000 0.1636%
03-09Buy

Executive/Senior Manager

4,475 0.0039%
01-11Free

Executive/Senior Manager

180,000 0.1592%
Change 5-day change 1-year change 3-year change Capi.($)
-5.54%+3.79%+24.91%+142.88% 4.51B
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.87B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.75B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -1.16%+0.13%+49.35%+206.64% 24.61B
Weighted average by Cap. -0.98%-1.35%+50.78%+176.51%

Financials

2026 *2027 *
Net sales - -
Net income -563M -492M -454M -420M -796M -53.69B -809M -5.43B -2.13B -26.45B -2.11B -2.07B -90.93B -587M -514M -474M -438M -831M -56.02B -845M -5.66B -2.22B -27.6B -2.21B -2.16B -94.88B
Net Debt -450M -394M -363M -336M -637M -42.96B -648M -4.34B -1.7B -21.16B -1.69B -1.65B -72.75B -523M -458M -422M -390M -740M -49.92B -753M -5.05B -1.98B -24.59B -1.97B -1.92B -84.55B
Logo Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Employees
59
Date Price Change Volume
26-07-10 US$38.86 -5.54% 2,158,829
26-07-09 US$41.14 +2.95% 1,722,342
26-07-08 US$39.96 -5.15% 3,341,213
26-07-07 US$42.13 +8.83% 4,359,821
26-07-06 US$38.71 +3.39% 2,122,614
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
38.86USD
Average target price
92.58USD
Spread / Average Target
+138.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VKTX Stock